Wegovy and Zepbound are two of the most requested prescription weight-loss injections, and both are approved specifically for chronic weight management — not just as a side effect of a diabetes medication. Here’s how they actually differ.
Active ingredient and mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist — it acts on a single hormone pathway to slow digestion and increase feelings of fullness. Zepbound contains tirzepatide, the same active ingredient as Mounjaro, which activates both the GIP and GLP-1 receptors. See our full guide to how tirzepatide injections work for more detail on the dual-receptor mechanism.
Approved use
Both are licensed specifically for chronic weight management, not just as a secondary effect of a diabetes treatment. Zepbound has one additional FDA-approved indication Wegovy doesn’t: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. If OSA is part of your health picture, that’s worth raising with your prescriber directly.
Weight loss in trial data
Trial results aren’t directly comparable across separate studies, but head-to-head data between semaglutide and tirzepatide (the active ingredients in Wegovy and Zepbound, respectively) has shown tirzepatide producing somewhat greater average weight loss. Individual results vary considerably, and these figures describe trial averages rather than a guaranteed personal outcome.
Dosing
Both are titrated gradually to manage side effects. Wegovy starts at 0.25mg weekly, increasing to a maintenance dose of 1.7mg or 2.4mg. Zepbound follows the same titration schedule as Mounjaro since it shares the same active ingredient — see our full dosing schedule for the week-by-week breakdown. Neither should be dose-adjusted without your prescriber’s guidance.
Side effects
Both share a similar gastrointestinal side-effect profile — nausea, diarrhoea, and constipation are the most commonly reported, usually easing as your body adjusts to each dose increase. See our Wegovy side effects guide and Mounjaro side effects guide (Zepbound shares Mounjaro’s active ingredient and side-effect profile) for a full breakdown.
Eligibility and how to order
Both are prescription-only. Place your order, and a licensed physician will speak with you directly on a live call to review your health history and confirm a prescription is medically appropriate before anything ships — see our full eligibility guide to check whether you’re likely to qualify first.
Which one is right for you?
If trial-data weight loss is your main priority, tirzepatide (Zepbound) has shown a slight edge over semaglutide (Wegovy) in head-to-head comparisons. If you also have moderate-to-severe obstructive sleep apnea, Zepbound is the only one of the two with an approved indication for it. Your prescriber will factor in your full medical history before recommending either.
Frequently Asked Questions
Is Zepbound stronger than Wegovy?
Zepbound (tirzepatide) has shown somewhat greater average weight loss than Wegovy (semaglutide) in head-to-head trial data, largely attributed to its dual-hormone mechanism, but individual response varies.
Can I switch from Wegovy to Zepbound?
Switching between GLP-1-class medications is possible but should only be done under clinical guidance, since dosing is not directly interchangeable.
Does Zepbound treat sleep apnea?
Yes — Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, in addition to weight management. Wegovy does not carry this indication.
Do Wegovy and Zepbound have the same side effects?
Both share a similar gastrointestinal side-effect profile, though individual tolerability can differ between the two.
Ready to find out which one fits your health profile? Start your free eligibility assessment and our clinical team will guide you.